Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
Verified

What's the purpose of this trial?

The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT).

This is an upcoming trial that has not yet started accepting patients.


What will happen during the trial?

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

Inclusion Criteria:

  • Patients with relapsed multiple myeloma undergoing salvage autologous transplant, either transplantation-naïve or with a history of previous autologous transplant.
  • Patients with identified relapsed/refractory disease which includes patients who have relapsed after at least two lines of therapy consisting of at least one of three standard agents including either a proteasome inhibitor or immunomodulatory agents or antiCD38 targeting therapy.
  • Patients with identified relapsed/refractory disease which includes patients who have relapsed after a single line of therapy consisting of at least one of three standard agents including either a proteasome inhibitor or immunomodulatory agents or antiCD38 targeting therapy.
    • 2020-1059 Version 3.0 24 May 2021 Page 10 of 47 Note: Induction therapy, autologous stem cell transplantation (ASCT) & maintenance therapy if given sequentially without intervening progressive disease (PD) are considered one line of therapy. Refractory MM may be defined as disease that is refractory to treatment while on therapy or that shows progression within 60 days of the last therapy.
  • Disease status, partial response, or better.
  • Age ≥ 18-year and ≤ 75-year.
  • Platelet count ≥ 50,000/mm3 & Hemoglobin ≥ 8 g/dL.
  • Karnofsky Performance Status (KPS) >70 (Appendix B.).
  • Adequate organ function (ALT ≤ 2.5 ULN; Total bilirubin ≤ 1.5 ULN or total bilirubin ≤ 1.5 ULN with direct bilirubin ≤ 35%; estimated glomerular filtration rate >30 mL/min per 1.73 m2

Exclusion Criteria:

  • Current corneal or epithelial disease (except mild punctate keratopathy).
  • Participant must not use contact lenses while participating in this study.
  • Participant must not have used an investigational drug or approved systemic antimyeloma therapy (including systemic steroids) within 14 days or five half-lives, whichever is shorter, preceding the first dose of study drug.
  • Participant must not have current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia (serum albumin < 3.0 gm/dl), esophageal or gastric varices, persistent jaundice, or cirrhosis. Note: Stable non-cirrhotic chronic liver disease (including Gilbert's syndrome or asymptomatic gallstones) or hepatobiliary involvement of malignancy is acceptable if otherwise meets entry criteria
  • Participant must not have presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM are eligible, provided they fulfil inclusion criteria
  • Participant must not have received prior treatment with a monoclonal antibody within 30 days of receiving the first dose of study drugs.
  • Participant must not have had major surgery ≤ 4 weeks before initiating study treatment.
  • The participant must not have any evidence of active mucosal or internal bleeding.
  • Participant must not have known immediate or delayed hypersensitivity reaction or idiosyncratic reactions to belantamab mafodotin or drugs chemically related to belantamab mafodotin, or any of the components of the study treatment.
  • Participant must not have an active infection requiring treatment 2020-1059 Version 3.0 24 May 2021 Page 11 of 47
  • Participant must not have evidence of cardiovascular risk, including any of the following:
    • Evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree atrioventricular (AV) block.
    • History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of screening.
    • Class III or IV heart failure as defined by the New York Heart Association functional classification system.
    • Uncontrolled hypertension.
  • Participant must not have known HIV infection, unless the participant can meet all of the following criteria:
    • Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/mL
    • CD4+ T-cell (CD4+) counts ≥350 cells/uL
    • No history of AIDS-defining opportunistic infections within the last 12 months
  • Participant must not have presence of hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study treatment. Note: presence of Hep B surface antibody (HBsAb) indicating previous vaccination will not exclude a participant.
  • Participant must not have positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study treatment.
    • Note: Participants with positive Hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained. Note: Hepatitis RNA testing is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.
  • Participant must not have invasive malignancies other than disease under study, unless the second malignancy has been medically stable for at least 2 years and, in the opinion of the principal investigators, will not affect the evaluation of the effects of clinical trial treatments on the currently targeted malignancy. Participants with curatively treated non-melanoma skin cancer may be enrolled without a 2-year restriction.
  • Participants must not be pregnant or lactating

Additional Trial Information

Phase 1

Enrollment: 20 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with MD Anderson Cancer Center to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors